FENNEC PHARMACEUTICALS INC.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Fennec Pharmaceuticals is a biopharmaceutical company that develops and markets PEDMARK, a sodium thiosulfate injection used to reduce the risk of hearing loss (ototoxicity) in pediatric patients receiving cisplatin chemotherapy for cancer.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Sayad Pierre SargisChief Medical Officer | Sell | $146K | 12,000at $12.18 | Aug 31, 2026 |
| Andrade RobertCHIEF FINANCIAL OFFICER | Sell | $884K | 75,000at $11.78 | Aug 27, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable FENC activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.